Cellectis SA
F:ZVAA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Cellectis SA
F:ZVAA
|
FR |
|
X
|
Xinhua Winshare Publishing and Media Co Ltd
HKEX:811
|
CN |
|
N
|
NWS Holdings Ltd
OTC:NWSZF
|
HK |
|
Askul Corp
TSE:2678
|
JP |
|
K
|
Kalvista Pharmaceuticals Inc
SWB:4XC1
|
US |
|
Worldline SA
OTC:WWLNF
|
FR |
|
C
|
Cronos Group Inc
XBER:7CI
|
CA |
|
L
|
L'Air Liquide Societe Anonyme pour l'Etude et l'Exploitation des Procedes Georges Claude SA
SWB:AIL
|
FR |
|
C
|
Cellectis SA
SWB:ZVA
|
FR |
|
B
|
BankUnited Inc
XBER:BNU
|
US |
|
A
|
Aristocrat Leisure Ltd
XMUN:AC8
|
AU |
|
N
|
NETGEAR Inc
SWB:NGJ
|
US |
|
D
|
Daedong Metals Co Ltd
KOSDAQ:020400
|
KR |
|
Torishima Pump Mfg Co Ltd
TSE:6363
|
JP |
|
V
|
Volatus Aerospace Inc
NEO:FLT
|
CA |
|
A
|
Amada Co Ltd
XMUN:AA2
|
JP |
|
A
|
Apetit Oyj
OMXH:APETIT
|
FI |
|
C
|
Carnival Corp
XBER:CVC1
|
US |
|
D
|
Dermapharm Holding SE
SWB:DMP
|
DE |
|
O
|
Oil States International Inc
XBER:OI2
|
US |
|
TuSimple Holdings Inc
OTC:TSPH
|
US |
|
U
|
Uniper SE
SWB:UN0
|
DE |
|
Lelon Electronics Corp
TWSE:2472
|
TW |
|
S
|
Stroeer SE & Co KgaA
XBER:SAX
|
DE |
Cellectis SA
Cellectis is a biotechnology company that uses gene-editing tools to design next-generation cell therapies, especially off-the-shelf CAR-T treatments for cancer. Instead of making each therapy from a patient’s own cells, it engineers donor immune cells so they can be manufactured in advance and used more like a standard drug. Its main work is developing these therapies and the underlying gene-editing methods that make them possible. The company makes money mainly through research and development collaborations, licensing its gene-editing technology, and if products win approval, through drug sales and partnering deals tied to those medicines. Its customers and partners are usually large drug companies, research organizations, and eventually hospitals and cancer specialists that would use the therapies in patients. In practice, Cellectis sits between basic gene-editing science and commercial cell therapy products. What makes the business different is that it focuses on allogeneic, or donor-derived, cell therapy rather than the more common patient-specific model. That approach aims to make treatment easier to manufacture, store, and distribute, while Cellectis’ gene-editing platform gives it a specific role as both a therapy developer and a technology supplier in the broader cell and gene therapy industry.
Cellectis is a biotechnology company that uses gene-editing tools to design next-generation cell therapies, especially off-the-shelf CAR-T treatments for cancer. Instead of making each therapy from a patient’s own cells, it engineers donor immune cells so they can be manufactured in advance and used more like a standard drug. Its main work is developing these therapies and the underlying gene-editing methods that make them possible.
The company makes money mainly through research and development collaborations, licensing its gene-editing technology, and if products win approval, through drug sales and partnering deals tied to those medicines. Its customers and partners are usually large drug companies, research organizations, and eventually hospitals and cancer specialists that would use the therapies in patients. In practice, Cellectis sits between basic gene-editing science and commercial cell therapy products.
What makes the business different is that it focuses on allogeneic, or donor-derived, cell therapy rather than the more common patient-specific model. That approach aims to make treatment easier to manufacture, store, and distribute, while Cellectis’ gene-editing platform gives it a specific role as both a therapy developer and a technology supplier in the broader cell and gene therapy industry.
Clinical win: lasme-cel (CD22) showed strong Phase I signals — 83% ORR at the recommended Phase II dose and 100% ORR in the target Phase II population — and converted all target patients to transplant-eligible status.
Pivotal timing: First interim analysis of the lasme-cel pivotal Phase II (40 patients) expected Q4 2026; BLA submission targeted H2 2028.
Another promising asset: eti-cel (dual CD20/CD22) reported an 88% ORR and 63% CR in early data; full Phase I data (including low‑dose IL-2 cohort) expected later in 2026 and pivotal start planned in 2027.
Manufacturing edge: Internally manufactured lasme-cel performed better than externally made product in Phase I (68% vs 28% ORR), supporting Cellectis' decision to internalize manufacturing.
Cash runway: Cash, cash equivalents, restricted cash and fixed term deposits were $211 million as of December 31, 2025, sufficient to fund operations into H2 2027 per management.
Partnership catalysts: Servier/Allogene cema-cel interim futility analysis on track for Q2 2026; Iovance IOV-4001 readout expected in 2026; collaboration with AstraZeneca ongoing (up to 10 programs).
Arbitration outcome: UCART19/ALLO-501 returned to Cellectis; arbitral decision did not affect cema-cel and Cellectis remains eligible for up to $340 million in Servier/Allogene milestones.
Safety profile: lasme-cel had low rates of high-grade neurotoxicity and CRS (Grade ≥3 CRS 2.5%, Grade ≥3 ICANS 5% at the RP2D).
